Overview

Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy

Status:
Completed

Trial end date:
2016-08-01

Target enrollment:

Participant gender:

Summary

Severe nausea and/or vomiting in patients receiving radiotherapy to the upper abdomen is common despite having received pre-medication with ondansetron, a standard preventive treatment. This study aims to reduce the incidence of significant nausea and/or vomiting with the addition of the NK1-antagonist aprepitant to standard ondansetron treatment. This study will also assess the safety and tolerability of prolonged administration of aprepitant over the 4 to 6 week period of radiation treatment.

Phase:

Phase 2

Details

Lead Sponsor:

University of Vermont

Collaborators:

Comprehensive Cancer Center of Wake Forest University
Mayo Clinic
Norris Cotton Cancer Center
University of Massachusetts, Worcester
Wake Forest University Health Sciences

Treatments:

Aprepitant
Fosaprepitant
Ondansetron